SEOUL -- Samsung Biologics has become South Korea's third-most-valuable company, besting the much larger Hyundai Motor thanks to its status as a rare winner in the coronavirus economy.
The drugmaker's shares soared this month after it won an order worth up to $362 million from a U.S. company developing antibody treatments for the virus.
